Crinetics appoints first general counsel
Nasdaq-listed Crinetics Pharmaceutical has hired Garlan Adams to fill the newly created position of general counsel.
Adams was previously an adviser to Indivior on a range of compliance and litigation matters related to product commercialization including patient access, interactions with healthcare professionals, sales, marketing and product life-cycle issues.
Before that, she was general counsel at Avanir Pharmaceuticals, a role in which she advised on matters related to compliance, clinical-stage development, sales, marketing, pricing and distribution, in addition to developing contracting processes and policies.
Earlier in her career, Adams worked at Eli Lilly & Company, Amylin Pharmaceuticals, Amgen and Onyx Pharmaceuticals, where she provided counsel on product labeling, launch readiness, medical affairs, manufacturing, sales, marketing, pricing and compliance.
Crinetics is a clinical-stage pharmaceutical company focused on novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Scott Struthers, founder and CEO, says in a statement: ‘Garlan has devoted her career to advising large and small pharmaceutical companies on the complexities of intellectual property [and] regulatory and compliance matters related to the development of therapeutics for the US and international markets. I am confident that having Garlan’s breadth of legal experience in clinical development and commercialization will be a tremendous asset to Crinetics.’